Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)Rodolfo Passalacqua, Caterina Caminiti, Matteo Dalla Chiesa et al.|Journal of Clinical Oncology|2005Cited by 3